(-)-Epigallocatechin Gallate (EGCG) (-)-表没食子儿茶素没食子酸酯

发表于由

描述

(-)-Epigallocatechin Gallate (EGCG)

产品信息                                                                                                            

产品名称 产品编号 CAS NO.      规格          价格（元） 
(-)-Epigallocatechin Gallate (EGCG) (-)-表没食子儿茶素没食子酸酯  MZ3651-20MG       989-51-5 20mg 238
(-)-Epigallocatechin Gallate (EGCG) (-)-表没食子儿茶素没食子酸酯 MZ3651-100MG 989-51-5 100mg 598
(-)-Epigallocatechin Gallate (EGCG) (-)-表没食子儿茶素没食子酸酯 MZ3651-500MG 989-51-5 500mg 2188

【温馨提示】：见我司的小分子化合物常见问题-金畔生物。 

产品描述

(-)-表没食子儿茶素没食子酸酯（(-)-Epigallocatechin Gallate, EGCG），CAS NO. 989-51-5，是从绿茶中提取纯化的一种成分，是儿茶素类化合物中最有效的活性成分，具有最强的抗氧化、抗癌、抗突变和抗血管生成活性，已被用于多种肿瘤包括肝癌、胃癌、皮肤癌、乳腺癌和结肠癌等的化学预防研究中，也对许多病毒包括HCV、HIV-1、HSV-1、HSV-2、腺病毒等有抑制作用。EGCG属于一种天然的多酚黄酮类抗生素，能够抑制端粒酶（telomerase）和DNA甲基转移酶（DNA methyltransferase），阻止EGF受体和HER-2受体的激活，也能抑制脂肪酸合成酶和谷氨酸脱氢酶的活性。是一种β-分泌酶抑制剂（IC50=1.6μM），能抑制淀粉样蛋白的组装，抑制由蛋白如Aβ，α-突触核蛋白和亨廷顿蛋白介导的淀粉样纤维的形成。能抑制细胞生长和选择性诱导A431和人胰腺癌细胞的凋亡。也是DNMT1抑制剂。

产品特性

1) CAS NO：989-51-5

2) 化学名：3,4,5-Trihydroxybenzoic acid (2R,3R)-3,4-dihydro-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-2H-1- benzopyran-3-yl ester

3) 同义名：Epigallocatechin gallate表没食子儿茶素没食子酸酯；Tea catechin儿茶素；NVP-XAA723；Teavigo；

4) 分子式：C22H18O11

5）分子量：458.37 g/mol

6）纯度：≥98% (HPLC)

7) 外观：类白色至白色粉末

8）溶解性：溶于H2O（5 mg/ml），DMSO（20 mg/ml），无水乙醇（45 mg/ml）

9）化学结构：

保存与运输方法

保存：-20ºC干燥保存，3年有效。

运输：常温运输。

使用方法【源自文献，仅作参考】

文献1，Rasheed NO et al.Nephro-toxic effects of intraperitoneally injected EGCG in diabetic mice: involvement of oxidative stress, inflammation and apoptosis. Sci Rep. 2017 Jan 18;7:40617. PMID: 28098182

体内研究：

动物模型（Animal Model）：Male Swiss albino mice weighing 25–30 g

药物配制（Preparation）：Teavigo, a highly purified extract containing 94% EGCG, dissolved in saline

注射剂量（Dosages）：Mice were randomly divided into 4 groups 8 mice each except group 4 in which 15 mice were used: Group 1 received saline served as normal control. Group 2 received a single dose of STZ (150 mg/kg, i.p) used as diabetic control.Group 3 received EGCG (100 mg/kg, i.p) dissolved in saline for 4 days. Group 4 received STZ as in group 2 then the diabetic animals were injected after 48 hrs with EGCG as in group 3. After 48 hrs of STZ injection, animals with blood glucose level ≥200 mg/dl were selected as diabetic animals.

给药途径（Administration）：Intraperitoneal (i.p.) injection
文献2，Pan C et al.NRF2 Plays a Critical Role in Both Self and EGCG Protection against Diabetic Testicular Damage. Oxid Med Cell Longev. 2017;2017:3172692. PMID: 28698767

体内研究：

动物模型（Animal Model）：Eight-week-old male mice that was successfully induced as diabetic mice.

药物配制（Preparation）：EGCG dissolved in normal saline

注射剂量（Dosages）：The diabetic mice and age-matched controls were treated daily by subcutaneously injected EGCG (100 mg/kg≥98%, dissolved in normal saline) or normal saline daily, for a total period of 24 weeks. Blood glucose was recorded on days 0, 28, 56, 84, 112, 140, and 168, after diabetes onset.

给药途径（Administration）：Subcutaneous (s.c.) injection

注意事项

为了您的安全和健康，请穿实验服并戴一次性手套操作。